Natera, Inc. (NTRA) News
Filter NTRA News Items
NTRA News Results
|Loading, please wait...|
NTRA News Highlights
- For NTRA, its 30 day story count is now at 3.
- Over the past 21 days, the trend for NTRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NTRA are CELL, DNA and III.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here.
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Natera Announces Commercial Payor Coverage for Signatera™
AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
AUSTIN, Texas, February 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook.
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Natera to Participate in Upcoming Investor Conferences
AUSTIN, Texas, February 24, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
AUSTIN, Texas, February 23, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors.
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
AUSTIN, Texas, February 21, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today
Natera stock broke definitively above its 200-day line Thursday after Medicare opted to reimburse for its breast cancer test.